Study of early estrogen's effect on heart disease similar to WHI findings

February 28, 2006

Researchers in The Department of Obstetrics, Gynecology & Reproductive Sciences at Yale have launched the Kronos Early Estrogen Prevention Study (KEEPS), which will further understanding of the possible beneficial effects on the heart and arteries and/or quality of life in recently menopausal women.

The study will explore whether beginning hormone therapy in women during the menopausal transition (ages 42 to 58) protects against atherosclerosis, the major cause of heart attacks.

This study is supported by the recent release of results from the Women's Health Initiative (WHI). That study initially suggested that there were few benefits of estrogen on atherosclerosis. The National Institutes of Health halted the study in 2002. Women in WHI were postmenopausal, with a mean age of 63, yet most women begin hormone treatment much younger, at the onset of menopausal symptoms. Today's study reports the results by age. The younger women, those 50 to 59-years-old, who used estrogen showed a beneficial effect on the heart.

"These findings are consistent with estrogen having a beneficial effect if used early, but a negative effect if used late," said Principal Investigator of the KEEPS trial at Yale, Hugh S. Taylor, M.D. "Estrogen seems to work by limiting the progression of atherosclerotic changes rather than treating established disease. You can't turn back the clock. Estrogen works by preventing disease, but it doesn't work if one goes for years without it. Newly menopausal women can use estrogen for relief of hot flushes and other menopausal symptoms without worrying about their heart. Women close to menopause might even see benefits for their heart."

The Yale team is seeking 90 healthy, recently menopausal women ages 42 to 58 for the trial that will study the effects of using pill and skin patch hormone therapy.

Compensation will be provided for participants accepted into the study.
For more information on KEEPS, visit or call Diane Wall, clinical research nurse coordinator at 203-785-4739 or

Yale University

Related Atherosclerosis Articles from Brightsurf:

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

T cells can shift from helping to harming in atherosclerosis
At La Jolla Institute for Immunology (LJI) researchers are dedicated to finding a way to stop plaques from forming in the first place.

New nanoparticle drug combination for atherosclerosis
Physicochemical cargo-switching nanoparticles (CSNP) designed by KAIST can help significantly reduce cholesterol and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation.

Atherosclerosis -- How a microRNA protects vascular integrity
Ludwig-Maximilian-Universitaet (LMU) in Munich researchers have discovered a hitherto unknown molecular function of a specific microRNA that preserves integrity of the endothelium and reduces the risk of atherosclerosis.

Atherosclerosis progresses rapidly in healthy people from the age of 40
A CNIC study published in JACC demonstrates that atheroma plaques extend rapidly in the arteries of asymptomatic individuals aged between 40 and 50 years participating in the PESA-CNIC-Santander study.

Scaling up a nanoimmunotherapy for atherosclerosis through preclinical testing
By integrating translational imaging techniques with improvements to production methods, Tina Binderup and colleagues have scaled up a promising nanoimmunotherapy for atherosclerosis in mice, rabbits and pigs -- surmounting a major obstacle in nanomedicine.

Bladder drug linked to atherosclerosis in mice
A drug used in the treatment of overactive bladder can accelerate atheroclerosis in mice, researchers at Karolinska Institutet in Sweden report in a study published in the Proceedings of the National Academy of Sciences (PNAS).

A new therapeutic target for blocking early atherosclerosis in progeria
Researchers at the Centro Nacional de Investigaciones Cardiovasculares and the Universidad de Oviedo have discovered a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome.

Protective mechanism against atherosclerosis discovered
Immune cells promoting inflammation play a crucial role in the development of atherosclerosis.

Atherosclerosis: Stopped on time
For the first time, LMU researchers are pointing out the influence of the internal clock on atherosclerosis.

Read More: Atherosclerosis News and Atherosclerosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to